ING-1(heMAb), a Monoclonal Antibody to Epithelial Cell Adhesion Molecule, Inhibits Tumor Metastases in a Murine Cancer Model

Neoplasia

Volumn 5, Issue 6, 2003, Pages 489-494

  Ruan, Harry H ^a   Scott, Kristen R ^a   Bautista, Eddie ^a   Ammons, W Steve ^a  

^a XOMA Corporation   (United States)

Author keywords

Cancer model; Ep CAM; ING 1(heMAb); Metastases; Micrometastases

Indexed keywords

CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ING1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; COLON CANCER; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR GROWTH;

EID: 0345791480     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80033-7     Document Type: Article

References (23)

1. Balzar M, Winter MJ, de Boer CJ, and Litvinov SV (1999). The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77, 699-12.
2. Litvinov SV, Balzar M, Winter MJ, Bakker HAM, Bruijn IHB, Prins F, Fleuren GJ, and Warnaar SO (1997). Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139, 1337-348.
3. Pantuck AJ, Seligson D, Huang Y, Horvath S, Bui M, Zisman A, Han K, Janzen N, Figlin R, and Beedegrun A (2003). Ep-CAM is an independent predictor of survival in renal cell carcinoma. Proc ASCO 22, 1602a.
4. Litvinov SV, Velders MP, Bakker HAM, Fleuren GJ, and Warnaar SO (1994). Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125, 437-46.
5. Gastl G, Spizzo G, Obrist P, Dunser M, and Mikuz G (2000). Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356, 1981-982.
6. Litvinov SV, van Driel W, van Rhijn CM, Bakker HA, van Krieken H, Fleuren GJ, and Warnaar SO (1996). Expression of Ep-CAM in cervical squamous epithelial correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148, 865-75.
7. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry H, and Koprowski H (1982). Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1, 762-65.
8. Studnicka GM, Soares S, Better M, Williams RE, Nadell R, and Horwitz A (1994). Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-complementarity-modulating residues. Protein Eng 17, 805-14.
9. Better M, Bohmann DJ, White ML, Forero A, de Bono JS, Hamond LA, Patnaik A, Takimoto C, LoBuglio A, Rowinsky EK, Tolcher AW, and Vanhove GF (2002). Recombinant human engineered ING-1 monoclonal antibody, ING-1(heMAb), exhibits minimal immunogenicity in patients with advanced adenocarcinomas. Proc ASCO 21, 20a.
10. Liao S-K, Horton L, Flahart RE, O'rear L, Crumpacker D, Imbaratto RR, Yannelli RR, and Robinson RK (1990). Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas. Hum Antib Hybridomas 1, 66-76.
11. Robinson RR, Chartier J, Chang CP, Horwtiz AH, and Better M (1991). Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities. Hum Antib Hybridomas 2, 84-93.
12. Colcher D, Hand PH, Nuti M, and Schlom J (1981). A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 78, 3199-203.
13. Ammons WS, Bauer RJ, Horwitz AH, Chen ZJ, Bautista E, Ruan HH, Abramova M, Scott KR, and Dedrick RL (2003). In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia 5, 146-54.
14. Masucci G, Lindemalm C, and Frodin J-E (1988). Effect of human blood mononuclear cell populations in antibody dependent cellular cytotoxicity (ADCC) using two murine (CO17-1A and BR55-2) and one chimeric (17-1A) monoclonal antibodies against a human colorectal carcinoma cell line (SW948). Hybridoma 7, 429-40.
15. Mannori G, Santoro D, Carter L, Corless C, Nelson RM, and Bevilacqua MP (1997). Inhibition of colon carcinoma cell lung colony formation by a soluble form of E-selectin. Am J Pathol 151, 233-43.
16. Giavazzi R, Garofalo A, Bani MR, Abbate M, Ghezzi P, Boraschi D, Mantovani A, and Dejana E (1990). Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice. Cancer Res 50, 4771-775.
17. Fidler I. J (2002). Critical determinants of metastasis. Semin Cancer Biol 12, 89-96.
18. Carter P (2001). Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1, 118-29.
19. Naundorf S, Preithner S, Mayer P, Lippold S, Wolf A, Hanakam F, Fitchner I, Kufer P, Raum T, Riethmuller G, Baeurle PA, and Dreier T (2002). In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 100, 101-10.
20. Velders MP, van Rhijn CM, Cornelissen IM, van Muijen GN, Briaire I, Hohlsten M, Fleuren GJ, Warnaar SO, and Litvinov SV (1996). The role of monoclonal antibody affinity in tumor immunotherapy evaluated in in vivo models for minimal residual disease. J Immunother 19, 245-56.
21. Velders MP, van Rhijn CM, Briaire IH, Fleuren GJ, Warnaar SO, and Litvinov SV (1995). Immunotherapy with low and high affinity monoclonal antibodies 17-1A and 323/A3 in a nude mouse xenograft carcinoma model. Cancer Res 55, 4398-403.
22. Johansson C, Segren S, and Lindholm L (1991). Tumor-growth suppression in nude mice by a murine monoclonal antibody: factors hampering successful therapy. Int J Cancer 48, 297-304.
23. Clynes RA, Towers TL, Presta LG, and Ravetch JV (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6, 443-46.